Dupilumab (Dupixent®) is indicated for treatment of moderate-to-severe atopic dermatitis in adult patients who are candidates for systemic therapy.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||13/11/2017|
|Rapid review completed||24/11/2017|
|Rapid Review outcome||Full pharmacoeconomic assessment recommended|
|Full pharmacoeconomic assessment commissioned by the HSE||29/11/2017|
|Pre-submission consultation with Applicant||18/06/2018|
|Submission received from Applicant||25/03/2019|
|Preliminary review sent to Applicant||05/06/2019|
|NCPE assessment re-commenced||01/07/2019|
|Factual accuracy sent to Applicant||08/11/2019|
|NCPE assessment re-commenced||22/11/2019|
|NCPE assessment completed||12/12/2019|
|NCPE assessment outcome||The NCPE recommends that dupilumab be considered for reimbursement if cost-effectiveness can be improved relative to existing treatments*|
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.